Novo Nordisk shares slide after 2030 strategic ambitions
Novo Nordisk (NVO) shares fell about 5.96% in Copenhagen trading after the company used its London Capital Markets Day to outline 2030 strategic ambitions under new CEO Mike Doustdar.
96% in Copenhagen trading after the Danish drugmaker used its London Capital Markets Day to outline 2030 strategic ambitions, its first full reset under new CEO Mike Doustdar. The company said it wants revenue from 2026 to 2030 to grow at a compound annual rate.